Creekmur Asset Management LLC Reduces Stake in Novo Nordisk A/S (NYSE:NVO)

Creekmur Asset Management LLC decreased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 87.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,021 shares of the company's stock after selling 7,428 shares during the period. Creekmur Asset Management LLC's holdings in Novo Nordisk A/S were worth $88,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Victory Capital Management Inc. boosted its stake in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after acquiring an additional 23,223 shares in the last quarter. Norman Fields Gottscho Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock valued at $5,482,000 after purchasing an additional 19,870 shares during the period. Bryn Mawr Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after purchasing an additional 30,420 shares in the last quarter. Versant Capital Management Inc acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $86,000. Finally, Talbot Financial LLC bought a new stake in Novo Nordisk A/S in the 4th quarter valued at about $4,066,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on NVO. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research note on Monday, December 23rd. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 21st. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Moderate Buy" and a consensus target price of $145.25.

Remove Ads

Novo Nordisk A/S Stock Down 1.7 %

Shares of NVO traded down $1.16 during trading hours on Thursday, reaching $67.08. 8,818,417 shares of the stock traded hands, compared to its average volume of 5,606,079. Novo Nordisk A/S has a 52 week low of $66.88 and a 52 week high of $148.15. The company has a market cap of $301.04 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 0.90 and a beta of 0.42. The stock has a fifty day simple moving average of $81.64 and a 200 day simple moving average of $97.47. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.